Skip to main content

Advertisement

Log in

Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF recombinants

  • Brief Report
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

To analyze humoral cross-reactivity to V3 peptides from subtype B and BF recombinant forms, plasma samples from 50 HIV-1-infected patients were characterized by sequencing fragments of the env and pol genes. An in-house EIA was performed using peptides corresponding to the 15 central amino acids of the V3 loop of gp120 from subtypes B (MN, SF2) and F1 and a consensus peptide from Argentinean BF recombinants. No differences were found with respect to the infecting subtype, but significant differences were found among the peptides. Reactivity was higher against the MN and BF peptides in both groups infected with subtype B (n = 28) and BF (n = 22) recombinants than against subtype F1 and SF2 peptides.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. McCutchan FE (2000) Understanding the genetic diversity of HIV-1. AIDS 14(Suppl 3):S31–S44

    CAS  PubMed  Google Scholar 

  2. Sabino EC, Shpaer EG, Morgado MG, Korber BT, Diaz RS et al (1994) Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. J Virol 68:6340–6346

    CAS  PubMed  Google Scholar 

  3. Carr JK, Salminen MO, Koch C, Gotte D, Artenstein AW et al (1996) Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol 70:5935–5943

    CAS  PubMed  Google Scholar 

  4. Marquina S, Leitner T, Rabinovich RD, Benetucci J, Libonatti O et al (1996) Coexistence of subtypes B, F, and as B/F env recombinant of HIV type 1 in Buenos Aires Argentina. AIDS Res Hum Retroviruses 12:1651–1654

    Article  CAS  PubMed  Google Scholar 

  5. Fernandez-Medina D, Jansson M, Rabinovich RD, Libonatti O, Wigzell H (1999) Identification of human immunodeficiency virus type 1 subtypes B and F B/F recombinant and dual infection with these subtypes in Argentina. Scand J Infect Dis 31:235–242

    Article  CAS  PubMed  Google Scholar 

  6. Comez Carrillo M, Salomon H, Pando MA, Kijak G, Avila MM (2001) Distribution of subtypes and recombinant of HIV. Situation in Argentina. Medicina (B Aires) 61:881–889

    CAS  Google Scholar 

  7. Carr JK, Avila M, Gomez Carrillo M, Salomon H, Hierholzer J et al (2001) Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS 15:F41–F47

    Article  CAS  PubMed  Google Scholar 

  8. Avila MM, Pando MA, Carrion G, Peralta LM, Salomon H et al (2002) Two HIV-1 epidemics in Argentina: different genetic subtypes associated with different risk groups. J Acquir Immune Defic Syndr 29:422–426

    PubMed  Google Scholar 

  9. Gomez Carrillo M, Avila M, Hierholzer J, Pando M, Martinez PL et al (2002) Mother-to-child HIV type 1 transmission in Argentina: BF recombinants have predominated in infected children since the mid-1980s. AIDS Res Hum Retroviruses 18:477–483

    Article  CAS  PubMed  Google Scholar 

  10. Turk G, Gherardi MM, Laufer N, Saracco M, Luzzi R et al (2008) Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants. J Virol 82:2853–2866

    Article  CAS  PubMed  Google Scholar 

  11. Humbert M, Dietrich U (2006) The role of neutralizing antibodies in HIV infection. AIDS Rev 8:51–59

    PubMed  Google Scholar 

  12. Zolla-Pazner S (2005) Improving on nature: focusing the immune response on the V3 loop. Hum Antibodies 14:69–72

    PubMed  Google Scholar 

  13. Teixeira SL, Bastos FI, Telles PR, Hacker MA, Brigido LF et al (2004) HIV-1 infection among injection and ex-injection drug users from Rio de Janeiro, Brazil: prevalence, estimated incidence and genetic diversity. J Clin Virol 31:221–226

    Article  PubMed  Google Scholar 

  14. Eyer-Silva WA, Couto-Fernandez JC, Morgado MG (2007) Molecular epidemiology of HIV type 1 in inner Rio De Janeiro State, Brazil. AIDS Res Hum Retroviruses 23:303–308

    Article  CAS  PubMed  Google Scholar 

  15. Buonaguro L, Tagliamonte M, Tornesello M, Buonaguro FM (2007) Evolution of the HIV-1 V3 region in the Italian epidemic. New Microbiol 30:1–11

    CAS  PubMed  Google Scholar 

  16. Sierra M, Thomson MM, Rios M, Casado G, Castro RO et al (2005) The analysis of near full-length genome sequences of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Chile, Venezuela and Spain reveals their relationship to diverse lineages of recombinant viruses related to CRF12_BF. Infect Genet Evol 5:209–217

    Article  CAS  PubMed  Google Scholar 

  17. Stanfield RL, Gorny MK, Zolla-Pazner S, Wilson IA (2006) Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J Virol 80:6093–6105

    Article  CAS  PubMed  Google Scholar 

  18. Cardozo T, Swetnam J, Pinter A, Krachmarov C, Nadas A et al (2009) Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies. AIDS Res Hum Retroviruses 25:441–450

    Article  CAS  PubMed  Google Scholar 

  19. Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN et al (2005) Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B V3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol 79:780–790

    Article  CAS  PubMed  Google Scholar 

  20. Pampuro SE, Calarota SA, Marquina SA, Rabinovich RD, Libonatti OV (1996) Reactivity of Argentine serum samples against synthetic V3-based HIV-1 peptides. J Acquir Immune Defic Syndr Hum Retrovirol 12:527–528

    CAS  PubMed  Google Scholar 

  21. Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C et al (2003) Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313:387–400

    Article  CAS  PubMed  Google Scholar 

  22. Teeraputon S, Louisirirojchanakul S, Auewarakul P (2005) N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies. Viral Immunol 18:343–353

    Article  CAS  PubMed  Google Scholar 

  23. Schilling R, Heil A, Langner K, Pohlmeyer K, Larsen M et al (2006) A multivalent HIV-vaccine: development of a plasmid DNA for the expression of HIV envelope glycoproteins with hypervariable V3-loop domains. Vaccine 24:4648–4650

    Article  CAS  PubMed  Google Scholar 

  24. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC et al (2008) Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 82:7369–7378

    Article  CAS  PubMed  Google Scholar 

  25. Eda Y, Takizawa M, Murakami T, Maeda H, Kimachi K et al (2006) Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J Virol 80:5552–5562

    Article  CAS  PubMed  Google Scholar 

  26. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J et al (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Peptides (MN, SF2, F) were obtained through the AIDS Research and Reference Reagent Program, AIDS Program, NIAID, NIH: HIV-1V3 peptides were obtained from the Division of AIDS, NIAID. This work was supported by grants to L.M.P. from the University of Buenos Aires (M043) and the National Agency for Promotion of Science and Technology (PICT 2007-1021).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Liliana Martinez Peralta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ambrosioni, J., Andreani, G., Acuipil, C. et al. Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF recombinants. Arch Virol 155, 2029–2034 (2010). https://doi.org/10.1007/s00705-010-0785-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-010-0785-y

Keywords

Navigation